

Special Issue

Breast Cancer Ecosystem: Genomic and Proteomic Profiling

Message from the Guest Editor

Breast cancer is a heterogeneous disease. The classification of breast cancer ranges from various histopathological subtypes based on cell morphology and biomarker expressions to molecular intrinsic subtypes according to gene expression patterns. Previously, genetic testing was conducted to determine the presence of mutations of certain breast cancer susceptibility genes. Nowadays, molecular prognostic assays are conducted to predict long-term outcomes of the disease. In this Special Issue, we aim to build a collection of research works that focus on advances in our understanding of the initiation and progression of breast cancer, particularly on the characterization of cancer and the surrounding micro-environment and their role in driving aggressiveness and recurrence risk. Research studies related to the identification of genetic modifications, genomics, proteomics, epigenetics, biomarker testing, prognostic assays and multi-omic signatures in any stage of breast cancer development are welcomed.

Guest Editor

Dr. Alison Cheung

Biomarker Imaging Research Laboratory, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada

Deadline for manuscript submissions

closed (15 April 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/185743

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))